Helix Biopharma Corp Stock Today
| HBP Stock | CAD 0.95 0.08 9.20% |
Performance0 of 100
| Odds Of DistressOver 64
|
Helix BioPharma is selling at 0.95 as of the 3rd of December 2024; that is 9.20% up since the beginning of the trading day. The stock's open price was 0.87. Helix BioPharma has more than 64 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Helix BioPharma Corp are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 14th of December 2022 and ending today, the 3rd of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. Helix BioPharma Corp. is headquartered in Richmond Hill, Canada. HELIX BIOPHARM operates under Biotechnology classification in Canada and is traded on Toronto Stock Exchange. The company has 49.02 M outstanding shares of which 781 shares are currently shorted by private and institutional investors with about 0.04 days to cover all short positions. More on Helix BioPharma Corp
Moving against Helix Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Helix Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Helix BioPharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Helix BioPharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman CEO | Jacek Antas | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
Helix BioPharma's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Helix BioPharma's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsHelix BioPharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Helix BioPharma's financial leverage. It provides some insight into what part of Helix BioPharma's total assets is financed by creditors.
| |||||
Helix BioPharma Corp (HBP) is traded on Toronto Exchange in Canada and employs 7 people. Helix BioPharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 46.57 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Helix BioPharma's market, we take the total number of its shares issued and multiply it by Helix BioPharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Helix BioPharma Corp operates under Biotechnology sector and is part of Health Care industry. The entity has 49.02 M outstanding shares of which 781 shares are currently shorted by private and institutional investors with about 0.04 days to cover all short positions.
Helix BioPharma Corp has accumulated about 938 K in cash with (5.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Check Helix BioPharma Probability Of Bankruptcy
Ownership AllocationHelix BioPharma Corp has a total of 49.02 Million outstanding shares. Roughly 97.85 (percent) of Helix BioPharma outstanding shares are held by general public with 2.15 % owned by insiders and only 0.0 pct. by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Helix Ownership Details
Helix BioPharma Corp Risk Profiles
Although Helix BioPharma's alpha and beta are two of the key measurements used to evaluate Helix BioPharma's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 5.3 | |||
| Standard Deviation | 8.18 | |||
| Variance | 66.99 | |||
| Risk Adjusted Performance | 0.0045 |
Helix Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Helix BioPharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Analyst Advice Now
Analyst AdviceAnalyst recommendations and target price estimates broken down by several categories |
| All Next | Launch Module |
Helix BioPharma Corporate Management
Elected by the shareholders, the Helix BioPharma's board of directors comprises two types of representatives: Helix BioPharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Helix. The board's role is to monitor Helix BioPharma's management team and ensure that shareholders' interests are well served. Helix BioPharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Helix BioPharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Namrata Malhotra | Corporate Secretary | Profile | |
| Dr MA | Head RD | Profile | |
| Srikanth Sola | Chief Officer | Profile | |
| Christof Boehler | Chief Officer | Profile |
Other Information on Investing in Helix Stock
Helix BioPharma financial ratios help investors to determine whether Helix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.